Clinical Trial Update: Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. [Phase 2]

View source ↗

Summary

A Phase 2 study updating safety and immunogenicity data for the Shigella4V2 bioconjugate vaccine in 9-month-old infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella4V2 vaccine (Shigella bioconjugate vaccine)

Snippet

Sponsor: LimmaTech Biologics AG | Conditions: Shigellosis | Phase 2 | Status: COMPLETED